<p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）周四股价上涨 6.1%。该股最高交易价为 32.00 美元，最后交易价为 31.64 美元。在交易中，共成交 64,228 股，较 374,984 股的平均交易量下降了 83%。该股此前收盘价为 29.83 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>PRAX 近期成为多份研究报告的主题。Truist Financial 将 Praxis Precision Medicines 的目标股价从 175.00 美元下调至 85.00 美元，并在 3 月 3 日的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 在 4 月 8 日的研究报告中重申了 “买入” 评级，并对 Praxis Precision Medicines 的目标股价设定为 85.00 美元。Robert W. Baird 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标股价从 117.00 美元下调至 73.00 美元，并给予该公司 “跑赢大盘” 评级。Wedbush 在 2 月 28 日的研究报告中将 Praxis Precision Medicines 的评级从 “持有” 下调至 “强烈卖出”。最后，HC Wainwright 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标股价从 120.00 美元下调至 105.00 美元，并对该股给予 “买入” 评级。一位研究分析师对该股给予了 “卖出” 评级，八位分析师对该公司的股票给予了 “买入” 评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 目前的共识评级为 “适度买入”，平均目标股价为 123.33 美元。</p>
<p><strong>查看我们对 PRAX 的最新股票分析</strong></p>
<h2>Praxis Precision Medicines 股价上涨 4.4%</h2>
<p>该公司 50 日简单移动平均线为 47.34 美元，200 日简单移动平均线为 64.42 美元。公司的市值为 6.2778 亿美元，市盈率为-3.02，贝塔值为 2.66。</p>
<p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近于 2 月 28 日发布了季度财报。该公司报告季度每股收益为（2.94 美元），低于市场共识预期的（2.76 美元）0.18 美元。该公司季度收入为 748 万美元，而分析师预期为 36 万美元。Praxis Precision Medicines 的股本回报率为-54.86%，净利润率为-9,409.22%。股票研究分析师预测，Praxis Precision Medicines, Inc.在当前财政年度将发布-10.22 美元的每股收益。</p>
<h2>Praxis Precision Medicines 的机构交易</h2>
<p>大型投资者最近买入和卖出了该公司的股票。GF Fund Management CO. LTD.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 48,000 美元。Graham Capital Management L.P.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 209,000 美元。KLP Kapitalforvaltning AS 在第四季度新购入 Praxis Precision Medicines 的股份，价值约 215,000 美元。最后，Envestnet Asset Management Inc.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 231,000 美元。机构投资者和对冲基金持有该公司 67.84% 的股份。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（获取免费报告）</p>
<p>Praxis Precision Medicines, Inc.是一家临床阶段的生物制药公司，专注于开发治疗中枢神经系统疾病的疗法，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行针对特发性震颤的第三阶段临床试验；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Praxis Precision Medicines</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>关税豁免为台湾半导体的反弹铺平道路</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>缓解关税：三只股票将从美元贬值中受益</li>
<li>什么使一只股票成为优质分红股？</li>
<li>博通与苹果的关系：人工智能机会与关税风险相遇</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Praxis Precision Medicines 吗？</h2>
<p>在你考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRAX

<p>Praxis Precision Medicines（纳斯达克代码：PRAX）股价上涨 6.1%，至 31.64 美元，尽管交易量大幅下降。分析师的评级不一，目标价格范围从 73 美元到 175 美元不等。该公司报告的季度每股收益为-2.94 美元，未能达到预期，市值为 6.2778 亿美元。机构投资者持有 67.84% 的股份。Praxis 专注于开发中枢神经系统疾病的治疗方案，目前有多个候选药物处于临床试验阶段</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) shares shot up 6.1% on Thursday . The stock traded as high as $32.00 and last traded at $31.64. 64,228 shares changed hands during trading, a decline of 83% from the average session volume of 374,984 shares. The stock had previously closed at $29.83.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）周四股价上涨 6.1%。该股最高交易价为 32.00 美元，最后交易价为 31.64 美元。在交易中，共成交 64,228 股，较 374,984 股的平均交易量下降了 83%。该股此前收盘价为 29.83 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>PRAX has been the subject of several recent research reports. Truist Financial decreased their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, March 3rd. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, April 8th. Robert W. Baird decreased their price objective on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an &#34;outperform&#34; rating for the company in a research report on Monday, March 3rd. Wedbush downgraded shares of Praxis Precision Medicines from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, February 28th. Finally, HC Wainwright cut their price target on Praxis Precision Medicines from $120.00 to $105.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $123.33.</p>
<div class="lb-trans"><p>PRAX 近期成为多份研究报告的主题。Truist Financial 将 Praxis Precision Medicines 的目标股价从 175.00 美元下调至 85.00 美元，并在 3 月 3 日的研究报告中给予该公司 “买入” 评级。Needham &amp; Company LLC 在 4 月 8 日的研究报告中重申了 “买入” 评级，并对 Praxis Precision Medicines 的目标股价设定为 85.00 美元。Robert W. Baird 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标股价从 117.00 美元下调至 73.00 美元，并给予该公司 “跑赢大盘” 评级。Wedbush 在 2 月 28 日的研究报告中将 Praxis Precision Medicines 的评级从 “持有” 下调至 “强烈卖出”。最后，HC Wainwright 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标股价从 120.00 美元下调至 105.00 美元，并对该股给予 “买入” 评级。一位研究分析师对该股给予了 “卖出” 评级，八位分析师对该公司的股票给予了 “买入” 评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 目前的共识评级为 “适度买入”，平均目标股价为 123.33 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PRAX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PRAX 的最新股票分析</strong></p>
</div><h2>Praxis Precision Medicines Stock Up 4.4 %</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股价上涨 4.4%</h2>
</div><p>The firm has a fifty day simple moving average of $47.34 and a 200-day simple moving average of $64.42. The company has a market cap of $627.78 million, a PE ratio of -3.02 and a beta of 2.66.</p>
<div class="lb-trans"><p>该公司 50 日简单移动平均线为 47.34 美元，200 日简单移动平均线为 64.42 美元。公司的市值为 6.2778 亿美元，市盈率为-3.02，贝塔值为 2.66。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). The firm had revenue of $7.48 million for the quarter, compared to analyst estimates of $0.36 million. Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. Equities research analysts forecast that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近于 2 月 28 日发布了季度财报。该公司报告季度每股收益为（2.94 美元），低于市场共识预期的（2.76 美元）0.18 美元。该公司季度收入为 748 万美元，而分析师预期为 36 万美元。Praxis Precision Medicines 的股本回报率为-54.86%，净利润率为-9,409.22%。股票研究分析师预测，Praxis Precision Medicines, Inc.在当前财政年度将发布-10.22 美元的每股收益。</p>
</div><h2>Institutional Trading of Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 的机构交易</h2>
</div><p>Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Praxis Precision Medicines during the fourth quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Praxis Precision Medicines during the 4th quarter worth approximately $48,000. Graham Capital Management L.P. purchased a new position in shares of Praxis Precision Medicines in the 4th quarter valued at approximately $209,000. KLP Kapitalforvaltning AS acquired a new position in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $215,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Praxis Precision Medicines during the fourth quarter worth approximately $231,000. Institutional investors and hedge funds own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。GF Fund Management CO. LTD.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 48,000 美元。Graham Capital Management L.P.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 209,000 美元。KLP Kapitalforvaltning AS 在第四季度新购入 Praxis Precision Medicines 的股份，价值约 215,000 美元。最后，Envestnet Asset Management Inc.在第四季度新购入 Praxis Precision Medicines 的股份，价值约 231,000 美元。机构投资者和对冲基金持有该公司 67.84% 的股份。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.是一家临床阶段的生物制药公司，专注于开发治疗中枢神经系统疾病的疗法，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行针对特发性震颤的第三阶段临床试验；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Praxis Precision Medicines</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>关税豁免为台湾半导体的反弹铺平道路</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>缓解关税：三只股票将从美元贬值中受益</li>
<li>什么使一只股票成为优质分红股？</li>
<li>博通与苹果的关系：人工智能机会与关税风险相遇</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Praxis Precision Medicines (NASDAQ:PRAX) 的股价上涨了 6.1% - 你是否应该购买？